Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05979428
Other study ID # NN6491-4973
Secondary ID U1111-1285-1575
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 7, 2023
Est. completion date March 10, 2025

Study information

Verified date August 2023
Source Novo Nordisk A/S
Contact Novo Nordisk
Phone (+1) 866-867-7178
Email clinicaltrials@novonordisk.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is testing a new study medicine to treat people with high levels of fat in the blood. The main aim of the study is to see if the new study medicine is safe and how it works in the body. Participants will either get NNC0491-6075 (the new study medicine) or placebo (a "dummy medicine" without active ingredients). Which treatment participants get is decided by chance. NNC0491-6075 is a new medicine which cannot be prescribed by doctors. The study has 3 parts (Part A, Part B and Part C). In Part A, investigators look at the effect of the study medicine after a single dose in healthy participants. Participants will get the study medicine either as injection(s) under the skin or as an infusion into a vein by the study staff. In Part B, investigators look at the effect of receiving the study medicine once weekly for four weeks in participants with high levels of fat in the blood but who are otherwise healthy. Participants will get the study medicine as injections under the skin by the study staff. In Part C, investigators look at the effect of the study medicine after a single dose in healthy participants of Japanese origin. Participants will get the study medicine either as injection(s) under the skin or as an infusion into a vein by the study staff. The study will last for about 18 months in total for Part A, Part B and Part C. Participants in Part A and Part C will be in the study for about 139 days each, from screening to the final visit while in Part B they will be in the study for about 160 days from screening to the final visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 106
Est. completion date March 10, 2025
Est. primary completion date February 3, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: Part A: - Men or women of non-childbearing potential - Aged 18-55 years (both inclusive) at the time of signing informed consent - Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests (presence of dyslipidaemia [example hypertriglyceridemia] is allowed) performed during the screening visit, as judged by the investigator - Body mass index (BMI) between 18.5 and 34.9 kilograms per square meter (kg/m^2) (both inclusive) at screening - Non-Japanese defined as not meeting inclusion criteria for Part C Part B: - Men or women of non-childbearing potential - Aged 18-64 years (both inclusive) at the time of signing informed consent - Dyslipidaemia at screening defined as all the below: Fasting serum triglycerides (TGs) greater than or equal to 150 milligrams per deciliter (mg/dL) and less than or equal to 500 mg/dL. Participants must have two measurements performed for eligibility. Both measurements must be greater than or equal to 135 mg/dL and at least one must be greater than or equal to 150 mg/dL. One of the measurements may be based on medical records or pre-screening results if the test is no more than 90 days old. If TGs are measured twice during the screening period, the tests must be performed with at least 4 days apart. TGs measured in the screening period must be after a 10 hour fast - Fasting low-density lipoprotein cholesterol (LDL-C) greater than or equal to 50 mg/dL and less than 190 mg/dL - Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator - BMI between 18.5 and 34.9 kg/m^2 (both inclusive) at screening - If on statin therapy the dose must have been stable for at least 8 weeks before screening and must be intended to remain stable throughout the study Part C: - Men or women of non-childbearing potential - Aged 18-55 years (both inclusive) at the time of signing informed consent - Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests (presence of dyslipidaemia [example, hypertriglyceridemia] is allowed) performed during the screening visit, as judged by the investigator - BMI between 18.5 and 34.9 kg/m^2 (both inclusive) at screening - Japanese defined as both biological parents of Japanese descent Exclusion Criteria: Part A,B and C: - Known or suspected hypersensitivity to study intervention(s) or related products - Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol - Use of prescription or non-prescription medicinal products within 14 days before screening. Exceptions are: Topical medications; occasional use of over-the-counter acetaminophen or Non-steroidal anti-inflammatory drugs (NSAIDs) at their labelled doses for mild pain; and statin therapy in Part B only if the dose has been stable for at least 8 weeks prior to screening and is intended to remain stable throughout the trial - Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values: Alanine aminotransferase greater than upper limit of normal (ULN) +50 percentage (%), Aspartate aminotransferase greater than ULN +50%, Total Bilirubin greater than ULN +20%, Creatine kinase greater than ULN +50%.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
NNC0491-6075
NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
Placebo
Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.

Locations

Country Name City State
United States Novo Nordisk Investigational Site Cypress California

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part A (SAD): Number of treatment emergent adverse events (TEAEs) Measured as count of events. An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A TEAE is defined as an AE that either has onset time after first trial product administration and no later than the end of study visit or Is present before first trial product administration and increases in severity during the treatment period and no later than the end of study visit. From pre-dose (Day 1) to end of study (Day 110)
Primary Part B (MAD): Number of treatment emergent adverse events (TEAEs) Measured as count of events. An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A TEAE is defined as an AE that either has onset time after first trial product administration and no later than the end of study visit or Is present before first trial product administration and increases in severity during the treatment period and no later than the end of study visit. From pre-dose (Day 1) to end of study (Day 131)
Primary Part C (SAD): Number of treatment emergent adverse events (TEAEs) Measured as count of events. An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A TEAE is defined as an AE that either has onset time after first trial product administration and no later than the end of study visit or Is present before first trial product administration and increases in severity during the treatment period and no later than the end of study visit. From pre-dose (Day 1) to end of study (Day 110)
Secondary Part A (SAD): AUC0-8, SD; the area under the NNC0491-6075 serum concentration-time curve from 0 to infinity after a single dose Measured as hours*nanomoles per liter (h*nmol/L) From pre-dose (Day 1) to end of study (Day 110)
Secondary Part A (SAD): Cmax, SD; the maximum serum concentration of NNC0491-6075 after a single dose Measured as nanomoles per liter (nmol/L) From pre-dose (Day 1) to end of study (Day 110)
Secondary Part A (SAD): t½, SD; the terminal half-life of NNC0491-6075 after a single dose Measured as hours (h) From pre-dose (Day 1) to end of study (Day 110)
Secondary Part A (SAD): tmax, SD; The time to maximum concentration of NNC0491-6075 after a single-dose (only from subcutaneous administration) Measured as hours From pre-dose (Day 1) to end of study (Day 110)
Secondary Part B (MAD): AUC0-168h, MD; the area under the NNC0491-6075 serum concentration-time curve from time 0 to 168 hours after last dose Measured as h*nmol/L From pre-dose (Day 22) to 168 hours after last dose (Day 29)
Secondary Part B (MAD): Cmax, MD; the maximum serum concentration of NNC0491-6075 after last dose Measured as nmol/L From pre-dose (Day 22) to end of study (Day 131)
Secondary Part B (MAD): t½, MD; the terminal half-life of NNC0491-6075 after last dose Measured as hours From pre-dose (Day 22) to end of study (Day 131)
Secondary Part B (MAD): tmax, MD; The time to maximum concentration of NNC0491-6075 after last dose Measured as hours From pre-dose (Day 22) to end of study (Day 131)
Secondary Part C (SAD): AUC0-8, SD; the area under the NNC0491-6075 serum concentration-time curve from 0 to infinity after a single dose Measured as h*nmol/L From pre-dose (Day 1) to end of study (Day 110)
Secondary Part C (SAD): Cmax, SD; the maximum serum concentration of NNC0491-6075 after a single dose Measured as nmol/L From pre-dose (Day 1) to end of study (Day 110)
Secondary Part C (SAD): t½, SD; the terminal half-life of NNC0491-6075 after a single dose Measured as hours From pre-dose (Day 1) to end of study (Day 110)
Secondary Part C (SAD): tmax, SD; The time to maximum concentration of NNC0491-6075 after a single-dose (only from subcutaneous administration) Measured as hours From pre-dose (Day 1) to end of study (Day 110)
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1